Development and Update of Guideline-based Quality Indicators in Lung Cancer

Abstract

Background In 2022, an update of the German lung cancer guideline, first published in 2010 and revised in 2018, was released. This article aims to show the process of updating, developing, and implementing guideline-based quality indicators (QI) into the certification system for lung cancer centers (LCC).

Methods A multidisciplinary and interprofessional working group revised the guideline QIs from 2018 using the strong recommendations of the guideline update, a systematic review for QIs, and the results of the implemented QIs from LCC.

Results For 4 out of 8 indicators from the 2018 guideline, the LCC showed an improved implementation of the requirements in the last 3 years (2018–2020). For 3 indicators, the median of the results was constant at a very high level (≥96% or 100%). Only the “adjuvant cisplatin-based chemotherapy” indicator showed declining values between 2018 and 2020. The target values and plausibility limits were well achieved by LCC. After updating the guideline, one QI from 2018 was not included in the new QI set due to the small denominator population. Based on the new strong recommendations, 8 new QIs were defined. From the QI set of the guideline update, 13 of 15 indicators (7 since 2018 and 6 from 2022 on) were adopted into the certification program.

Conclusions The guideline recommendations are implemented by LCC at a high level. The process presented confirms the successful implementation of the so-called quality cycle in oncology. The QIs developed by the German Guideline Program in Oncology (GGPO) are adopted by the certification program. The implementation of the QI is measured in LCC, evaluated by the German Cancer Society (DKG), and reflected back to the GGPO. The “real world” data have led to the deletion of one QI and show a high implementation of most QIs in LCC.

Zusammenfassung

Hintergrund Die 2010 erstmals publizierte und 2018 überarbeitete deutsche S3-Leitlinie Lungenkarzinom (LL) wurde 2022 aktualisiert. Ziel dieses Artikels ist es, den Prozess der Aktualisierung und Entwicklung der auf den starken Empfehlungen der Leitlinie basierenden Qualitätsindikatoren (QI) und die Implementierung dieser QI in das Zertifizierungssystem für Lungenkrebszentren (LZ) darzustellen.

Methoden Nach systematischem Review überarbeitete eine multidisziplinäre und interprofessionelle Arbeitsgruppe unter Berücksichtigung der QI-Ergebnisse der zertifizierten LZ und auf Grundlage der starken Empfehlungen des LL-Updates die Leitlinien-QI aus dem Jahr 2018.

Ergebnisse Die LZ haben in den letzten 3 Jahren (2018–2020) ihre Ergebnisse für 4 von 8 Indikatoren (LL 2018) verbessert. Bei 3 Indikatoren ist der Median der Ergebnisse auf einem sehr hohen Niveau (≥96% oder 100%) konstant. Lediglich der Indikator „Adjuvante Cisplatin-basierte Chemotherapie“ weist zwischen 2018 und 2020 rückläufige Werte auf. Die Sollvorgaben und Plausibilitätsgrenzen werden von den LZ gut erreicht. Nach der Aktualisierung der Leitlinie wurde ein QI (LL-2018) aufgrund eines kleinen Patientenkollektivs nicht in das neue QI-Set aufgenommen. Basierend auf den neuen starken Empfehlungen wurden 8 neue QI definiert. Aus dem QI-Set der Leitlinienaktualisierung sind 13 von 15 Indikatoren (7 seit 2018 und 6 weitere ab 2022) in das Zertifizierungsprogramm aufgenommen worden.

Schlussfolgerungen Die Empfehlungen der Leitlinie werden von den LZ auf hohem Niveau umgesetzt. Der dargestellte Prozess bestätigt die erfolgreiche Umsetzung des sog. Qualitätszyklus in der Onkologie: Die vom Leitlinienprogramm Onkologie (OL) entwickelten QI werden in das Zertifizierungsprogramm übernommen. Die Umsetzung der QI wird in den LZ gemessen, von der Deutschen Krebsgesellschaft (DKG) bewertet und an das OL zurückgespiegelt. Die „real-world“-Daten haben zur Streichung eines QI geführt und zeigen in den zertifizierten Lungenkrebszentren eine hohe Umsetzung der meisten QI.

Keywords

lung cancer - quality indicators - key figures - quality of care - guideline

Schlüsselwörter

Lungenkarzinom - Qualitätsindikatoren - Kennzahlen - Versorgungsqualität - Leitlinie

Publication History

Received: 29 August 2023

Accepted after revision: 03 November 2023

Article published online:
02 September 2024

• References

• 1 Zentrum für Krebsregisterdaten. Krebs – Lungenkrebs. 2022 Accessed December 09, 2022 at: https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Lungenkrebs/lungenkrebs_node.html
• 2 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft/Deutsche Krebshilfe/AWMF). Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms (S3-Leitlinie, Langversion 2.0), AWMF-Registernummer: 020/007OL. 2022 Accessed November 30, 2022 at: https://www.leitlinienprogramm-onkologie.de/leitlinien/lungenkarzinom/
• 3 Remon J, Soria JC, Peters S. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy. Ann Oncol 2021; 32: 1637-1642 DOI: 10.1016/j.annonc.2021.08.1994. (PMID: 34481037)
• 4 Planchard D, Popat S, Kerr K. et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up (updated 15–09–2020). Ann Oncol 2018; 29: 192-237
• 5 Dingemans AMC, Früh M, Ardizzoni A. et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021; 32: 839-853 DOI: 10.1016/j.annonc.2021.03.207. (PMID: 33864941)
• 6 Lindeman NI, Cagle PT, Aisner DL. et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med 2018; 142: 321-346 DOI: 10.5858/ARPA.2017-0388-CP.
• 7 Toubat O, Atay SM, Kim AW. et al. Disparities in Guideline-Concordant Treatment for Pathologic N1 Non-Small Cell Lung Cancer. Ann Thorac Surg 2020; 109: 1512-1520 DOI: 10.1016/j.athoracsur.2019.11.059. (PMID: 31982443)
• 8 Stokes SM, Massarweh NN, Stringham JR. et al. Clinical-Pathologic Correlation and Guideline Concordance in Resectable Non-Small Cell Lung Cancer. Ann Thorac Surg 2019; 108: 837-844 DOI: 10.1016/j.athoracsur.2019.03.062. (PMID: 31026431)
• 9 Lindqvist J, Jekunen A, Sihvo E. et al. Effect of adherence to treatment guidelines on overall survival in elderly non-small-cell lung cancer patients. Lung Cancer 2022; 171: 9-17 DOI: 10.1016/J.LUNGCAN.2022.07.006.
• 10 Farrow NE, An SJ, Speicher PJ. et al. Disparities in guideline-concordant treatment for node-positive, non-small cell lung cancer following surgery. J Thorac Cardiovasc Surg 2020; 160: 261-271.e1 DOI: 10.1016/J.JTCVS.2019.10.102.
• 11 Sterbis E, Liang R, Trivedi P. et al. Lack of adherence to guideline-based imaging prior to subsequent radiation in patients with non-small cell lung cancer: Impact on patient outcomes. J Nucl Med 2023; 64: 75-81 DOI: 10.2967/jnumed.122.264131.
• 12 Bousema JE, Heineman DJ, Dijkgraaf MGW. et al. Adherence to the mediastinal staging guideline and unforeseen N2 disease in patients with resectable non-small cell lung cancer: Nationwide results from the Dutch Lung Cancer Audit – Surgery. Lung Cancer 2020; 142: 51-58 DOI: 10.1016/J.LUNGCAN.2020.02.008.
• 13 Odell DD, Feinglass J, Engelhardt K. et al. Evaluation of adherence to the Commission on Cancer lung cancer quality measures. J Thorac Cardiovasc Surg 2019; 157: 1219-1235 DOI: 10.1016/J.JTCVS.2018.09.126. (PMID: 31343410)
• 14 Griesshammer E, Wesselmann S, Beckmann MW. et al. Quality assurance and improvement in oncology using guideline-derived quality indicators – results of gynaecological cancer centres certified by the German cancer society (DKG). J Cancer Res Clin Oncol 2023; 149: 1703-1715 DOI: 10.1007/S00432-022-04060-8/FIGURES/1. (PMID: 35657567)
• 15 Rückher J, Lobitz J, Follmann M. et al. Guideline-Based Quality Indicators for Kidney and Bladder Cancer in Germany: Development and Implementation. Urol Int 2022; 106: 360-367 DOI: 10.1159/000517893. (PMID: 34384078)
• 16 German Guideline Program in Oncology (GGPO) (German Cancer Society; German Cancer Aid; Association of the Scientific Medical Societies). Development of guideline-based quality indicators: Methodology for the German Guideline Program in Oncology, version 3.0. 2021 Accessed November 30, 2022 at: https://www.leitlinienprogramm-onkologie.de/methodik/grundlegende-informationen-zur-methodik/ DOI: 10.1007/s00432-013-1464-7
• 17 Mensah J, Graeven U, Wesselmann S. Nationales Zertifizierungsprogramm Krebs: Ausgangspunkt − Entwicklung − Ausblick. Onkologe 2017; 23: 711-718 DOI: 10.1007/S00761-017-0272-0/METRICS.
• 18 German Cancer Society (DKG). Annual Report of the Certified Lung Cancer Centres 2022. 2022 Accessed November 30, 2022 at: https://ecc-cert.org/annual-reports/
• 19 Follmann M, Eigentler T, Adam H. et al. Quality assurance in melanoma care: guideline-based quality indicators for melanoma – implementation, evaluation and update process. J Dtsch Dermatol Ges 2020; 18: 848-857 DOI: 10.1111/DDG.14149. (PMID: 32578392)
• 20 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft/Deutsche Krebshilfe/AWMF). Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms, Leitlinienreport Version 2.0. 2022 Accessed December 08, 2022 at: https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Lungenkarzinom/Version_2/LL_Lungenkarzinom_Leitlinienreport_2.0.pdf
• 21 Vrijens F, De Gendt C, Verleye L. et al. Quality of care and variability in lung cancer management across Belgian hospitals: a population-based study using routinely available data. Int J Qual Health Care 2018; 30: 306-312 DOI: 10.1093/INTQHC/MZY027. (PMID: 29506181)
• 22 Information Services Division of the NHS National Services Scotland. Lung cancer quality performance indicators. 2020 Accessed December 07, 2022 at: https://beta.isdscotland.org/find-publications-and-data/conditions-and-diseases/cancer-qpis/lung-cancer/
• 23 Paz-Ares L, Gondos A, Saldana D. et al. Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study. Lung Cancer 2022; 167: 41-48 DOI: 10.1016/j.lungcan.2022.01.021.
• 24 Adizie JB, Tweedie J, Khakwani A. et al. Biomarker Testing for People with Advanced Lung Cancer in England. JTO Clin Res Rep 2021; 2: 100176 DOI: 10.1016/j.jtocrr.2021.100176.
• 25 Ismail RK, Schramel FMNH, Dartel M van. et al. The Dutch Lung Cancer Audit: Nationwide quality of care evaluation of lung cancer patients. Lung Cancer 2020; 149: 68-77 DOI: 10.1016/J.LUNGCAN.2020.08.011.
• 26 Li Y, Appius A, Pattipaka T. et al. Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA. PLoS One 2019; 14 DOI: 10.1371/JOURNAL.PONE.0209709.
• 27 Nadler E, Vasudevan A, Wang Y. et al. Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network. Cancer Treat Res Commun 2022; 31: 100522 DOI: 10.1016/J.CTARC.2022.100522. (PMID: 35189530)
• 28 Federal Ministry of Health. Ziele des Nationalen Krebsplans [Goals of the National Cancer Plan]. Accessed September 16, 2022 at: https://www.bundesgesundheitsministerium.de/themen/praevention/nationaler-krebsplan/handlungsfelder/ziele-des-nationalen-krebsplans.html
• 29 Brims FJH, Kumarasamy C, Nash J. et al. Hospital-based multidisciplinary lung cancer care in Australia: a survey of the landscape in 2021. BMJ Open Resp Res 2022; 9: 1157 DOI: 10.1136/bmjresp-2021-001157. (PMID: 35039312)
• 30 Beck N, Hoeijmakers F, Wiegman EM. et al. Lessons learned from the Dutch Institute for Clinical Auditing: The Dutch model for quality assurance in lung cancer treatment. J Thorac Dis 2018; 10: S3472-S3485 DOI: 10.21037/JTD.2018.04.56.
• 31 O’Brien MER, Paz-Ares L, Jha N. et al. EORTC-1416-LCG/ETOP 8–15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use. Journal of Clinical Oncology 2022; 40: 8512-8512 DOI: 10.1200/JCO.2022.40.16_SUPPL.8512.
• 32 New adjuvant trial of Chemotherapy vs Chemo-immunotherapy (NADIM-ADJUVANT) (NCT04564157). Accessed October 17, 2023 at: https://clinicaltrials.gov/study/NCT04564157
• 33 Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST Chemo-IO (ACCIO). Accessed October 17, 2023 at: https://clinicaltrials.gov/study/NCT04267848 DOI: 10.2217/imt-2021-0019
• 34 Dickhoff C, Dahele M, Joop De Langen A. et al. Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013. J Thorac Oncol 2016; 11: 566-572 DOI: 10.1016/j.jtho.2016.01.002.
• 35 Evers J, Jaeger K de, Hendriks LEL. et al. Trends and variations in treatment of stage I–III non-small cell lung cancer from 2008 to 2018: A nationwide population-based study from the Netherlands. Lung Cancer 2021; 155: 103-113 DOI: 10.1016/J.LUNGCAN.2021.03.013.
• 36 Miller ED, Fisher JL, Haglund KE. et al. Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database. Radiat Oncol 2018; 13: 196 DOI: 10.1186/s13014-018-1142-7.